Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR
12. Dezember 2024 07:30 ET
|
FACT.MR
Rockville, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Cutaneous T-cell lymphoma diagnosis market is estimated to...
萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准
16. Juli 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
万联行获得Targretin®（Bexarotene 贝沙罗汀）在香港用于皮肤T细胞淋巴瘤的市场批准
16. Juli 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司（“Main Life”）今天宣布Targretin®（贝沙罗汀）胶囊在香港获得上市许可，用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 （Cutaneous T-cell...
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
16. Juli 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12. März 2024 02:30 ET
|
Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29. Januar 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29. Januar 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
Global Cutaneous T-cell Lymphoma (CTCL) Treatment Market to be Driven by Rising Prevalence of Lymphoma Cancer and Growing Advances in Cancer Treatment at a CAGR of ~5% over 2022-2030
15. Juli 2022 10:47 ET
|
Research Nester
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The different types of cancer that arise in the immune cells, also known as lymphocytes, are commonly termed as lymphoma. It is estimated that in the...
Global Cutaneous T-cell Lymphoma Market is projected to be worth USD 3531.5 Million by 2030 I SPER Market Research
30. November 2021 12:07 ET
|
SPER Market Research Pvt. Ltd.
New York, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 billion by 2030. The growth is primarily...
Mycosis Fungoides Treatment Market Report 2021-2028 | Size, Share, Growth, Trends, Covid-19 Impact, Statistics, Competitive Landscape, Regional Analysis, Forecast
23. Juli 2021 02:55 ET
|
Fortune Business Insights
Pune, India, July 23, 2021 (GLOBE NEWSWIRE) -- The global mycosis fungoides treatment market is set to gain impetus from the increasing recommendation of various treatment options by physicians. It...